CAM
SPRY icon

Cresset Asset Management’s ARS Pharmaceuticals SPRY Stock Holding History

Cresset Asset Management’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$242K Hold
30,152
– – ﹤0.01% 1499
2026
Q1 		$242K Hold
30,152
– – ﹤0.01% 1380
2025
Q4 		$351K Hold
30,152
– – ﹤0.01% 1224
2025
Q3 		$303K Hold
30,152
– – ﹤0.01% 1236
2025
Q2 		$526K Buy
30,152
+1,900
+7% +$27.4K ﹤0.01% 908
2025
Q1 		$355K Buy
28,252
+500
+2% +$6.02K ﹤0.01% 1233
2024
Q4 		$293K Buy
27,752
+3,270
+13% +$45.8K ﹤0.01% 1363
2024
Q3 		$355K Hold
24,482
– – ﹤0.01% 1719
2024
Q2 		$208K Buy
+24,482
New +$217K ﹤0.01% 1880

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Cresset Asset Management's SPRY Position: Q2 2026 in Review

Cresset Asset Management held its ARS Pharmaceuticals (SPRY) position steady in Q2 2026 at 30,152 shares worth $242K. The position accounts for ﹤0.01% of the portfolio, ranked #1499.

Cresset Asset Management first reported a position in SPRY in Q2 2024 and has held it in 9 quarters since. The position peaked at $526K in Q2 2025. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Cresset Asset Management held 30,152 shares of ARS Pharmaceuticals worth $242K as of Q2 2026.
  • Cresset Asset Management left its ARS Pharmaceuticals share count unchanged in Q2 2026.
  • ARS Pharmaceuticals made up ﹤0.01% of Cresset Asset Management's portfolio in Q2 2026, its #1499 holding.
  • Cresset Asset Management first reported a position in ARS Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
  • Cresset Asset Management's ARS Pharmaceuticals position peaked at $526K in Q2 2025.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Cresset Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.